Potentiation of the action of anandamide on hippocampal slices by the fatty acid amide hydrolase inhibitor, palmitylsulphonyl fluoride (AM 374)

European Journal of Pharmacology

Volumn 383, Issue 1, 1999, Pages 9-14

  Gifford, Andrew N ^a   Bruneus, Magalie ^a   Lin, Sonyuan ^b   Goutopoulos, Andreas ^b   Makriyannis, Alexandros ^b   Volkow, Nora D ^a   Gatley, S John ^a  

^a BROOKHAVEN NATIONAL LABORATORY   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Acetylcholine; Anandamide; Brain slice; Cannabinoid receptor; Fatty acid amide hydrolase; Hippocampus

Indexed keywords

ACETYLCHOLINE; AM 374; AMIDASE; AMIDE; ANANDAMIDE; CANNABINOID; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; FATTY ACID; FATTY ACID AMIDASE; HYDROLASE; N (4 HYDROXYPHENYL)ARACHIDONYLETHANOLAMIDE; PALMITYLSULFONYL FLUORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME INHIBITION; HIPPOCAMPUS; MALE; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; RAT;

ACETYLCHOLINE; AMIDOHYDROLASES; ANIMALS; ARACHIDONIC ACIDS; CANNABINOIDS; CYCLOHEXANOLS; DRUG SYNERGISM; ELECTRIC STIMULATION; ENZYME INHIBITORS; HIPPOCAMPUS; MALE; MORPHOLINES; NAPHTHALENES; PALMITATES; POLYUNSATURATED ALKAMIDES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CANNABINOID; RECEPTORS, DRUG;

EID: 0033592583     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00609-3     Document Type: Article

References (18)

1. Adams I.B., Ryan W., Singer M., Thomas B.F., Compton D.R., Razdan R.K., Martin B.R. Evaluation of cannabinoid receptor binding and in vivo activities for anandamide analogs. J. Pharmacol. Exp. Ther. 273:1995;1172-1181.
2. Beltramo M., Stella N., Calignano A., Lin S.Y., Makriyannis A., Piomelli D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science. 277:1997;1094-1097.
3. Calignano A., La Rana G., Beltramo M., Makriyannis A., Piomelli D. Potentiation of anandamide hypotension by the transport inhibitor, AM 404. Eur. J. Pharmacol. 337:1997;R1-R2.
4. Childers S.R., Sexton T., Roy M.B. Effects of anandamide on cannabinoid receptors in rat brain membranes. Biochem. Pharmacol. 47:1994;711-715.
5. Deutsch D.G., Chin S.A. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem. Pharmacol. 46:1993;791-796.
6. Deutsch D.G., Lin S., Hill W.A.G., Morse K.L., Salehani D., Arreaza G., Omeir R.L., Makriyannis A. Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to the cannabinoid receptor. Biochem. Biophys. Res. Comm. 231:1997;217-221.
7. Di Marzo V., Fontana A., Cadas H., Schinelli S., Cimino G., Schwartz J.C., Piomelli D. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature. 372:1994;686-691.
8. Gifford A.N., Ashby C.R. Electrically-evoked acetylcholine release from hippocampal slices is inhibited by the cannabinoid receptor agonist, WIN 55212-2, and is potentiated by the cannabinoid antagonist, SR-141716A. J. Pharmacol. Exp. Ther. 277:1996;1431-1436.
9. Gifford A.N., Samiian L., Gatley S.J., Ashby C.R. Examination of the effect of the cannabinoid receptor agonist, CP-55,940, on neurotransmitter release from brain slices. Eur. J. Pharmacol. 324:1997;187-192.
10. Gifford A.N., Bruneus M., Gatley S.J., Lan R., Makriyannis A., Volkow N.D. Large receptor reserve for cannabinoid actions in the central nervous system. J. Pharmacol. Exp. Ther. 288:1998;478-483.
11. Goparaju S.K., Ueda N., Yamaguchi H., Yamamoto S. Anandamide amidohydrolase reacting with 2-arachidonoylglycerol, another cannabinoid receptor ligand. FEBS Lett. 422:1998;69-73.
12. Hillard C.J., Edgemond W.S., Jarrahian A., Campbell W.B. Accumulation of N-arachidonoylethanolamine (anandamide) into cerebellar granule cells occurs via facilitated diffusion. J. Neurochem. 69:1997;631-638.
13. Lang W., Qin C., Lin S., Khanolkar A.D., Goutopoulos A., Fan P., Abouzid K., Meng Z., Biegel D., Makriyannis A. Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase. J. Med. Chem. 42:1999;896-902.
14. Mechoulam R., Ben-Shabat S., Hanus L., Ligumsky M., Kaminski N.E., Schatz A.R., Gopher A., Almog S., Martin B.R., Compton D.R., Pertwee R.G., Griffin G., Bayewitch M., Barg J., Vogel Z. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50:1995;83-90.
15. Pertwee R.G., Fernando S.R., Griffin G., Abadji V., Makriyannis A. Effect of phenylmethylsulphonyl fluoride on the potency of anandamide as an inhibitor of electrically evoked contractions in two isolated tissue preparations. Eur. J. Pharmacol. 272:1995;73-78.
16. Showalter V.M., Compton D.R., Martin B.R., Abood M.E. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J. Pharmacol. Exp. Ther. 278:1996;989-999.
17. Stella N., Schweitzer P., Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature. 388:1997;773-778.
18. Thomas E.A., Cravatt B.F., Danielson P.E., Gilula N.B., Sutcliffe J.G. Fatty acid amide hydrolase, the degradative enzyme for anandamide and oleamide, has selective distribution in neurons within the rat central nervous system. J. Neurosci. Res. 50:1997;1047-1052.